No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Devices
ViroGates A/S is a Danish firm specializing in the creation and commercialization of prognostic diagnostic solutions for the medical field. Its flagship product, suPARnostic, is a blood test designed to quantify the soluble urokinase plasminogen activator receptor (suPAR) protein within a patient's circulatory system. This innovative tool empowers hospital emergency rooms to refine their clinical assessments regarding the admission or release of patients with acute medical conditions, thereby contributing to lower healthcare expenditures. Beyond this, ViroGates also supplies several other suPARnostic variations: suPARnostic TurbiLatex, a specialized latex particle-enhanced turbidimetric immunoassay for precise suPAR quantification in specific human plasma samples (K2-EDTA or lithium heparin); the suPARnostic Quick Triage kit, optimized for rapid early warning and patient categorization at the point of care; and suPARnostic ELISA, which delivers comprehensive quantitative readings. The prognostic capabilities of suPAR extend across a broad spectrum of medical conditions, encompassing cardiovascular, renal, oncological, diabetic, hepatic, infectious, respiratory, and rheumatic diseases. Established in 2000, the company maintains its headquarters in Birkerød, Denmark.
www.virogates.comNo one on the platform currently holds VIRO.CO.
No tracked institution reports a position in VIRO.CO as of their last filing.
No one on the platform has traded VIRO.CO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 8.4% | -0.2% | ||||
| Profit Margin % | -195.9% | -191.2% | -273.5% | |||
| Free Cash Flow Margin % | -77.7% | -174.0% | -261.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $191M | +31.6% | $20.12 | $20.12–$20.12 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 2 of the last 2 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-20 | $-1.00 | $-0.06 | +93.7% |
| 2026-05-08 | $-1.00 | $-0.28 | +72.1% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| VIRO.COViroGates A/S | $10.10 | +0.00% | $94M | — |
| BRAINP.COBrain+ A/S | $0.00 | +0.00% | $5M | — |
| MONSO.COMonsenso A/S | $0.29 | +14.17% | $19M | — |
| PEG.COPharma Equity Group A/S | $0.08 | +0.00% | $97M | — |
| SMSMED.COScandinavian Medical Solutions A/S | $2.53 | -4.53% | $70M | — |
| STENO.COStenocare A/S | $0.95 | +2.80% | $41M |
Source: Financial Modeling Prep · peers by sector/industry
| — |